INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines

Procept BioRobotics is facing a securities class action over alleged unlawful conduct, amid multiple guidance/sales disappointments. Handpiece sales missed and/or fell short of guidance across quarters—e.g., U.S. sales declined from 13,225 (Q3’25) to 9,400 (Q4’25), a nearly 30% sequential drop—prompting stock declines of ~16%, ~10%+, and ~18% over successive two-day periods. The latest court timeline calls for lead-plaintiff selection by Sept. 22, 2026.

Analysis

This is less a litigation story than a credibility reset: the market will treat every future update from PRCT as a sell-through check, not a sell-in headline. In small-cap medtech, that typically keeps the multiple suppressed even after the core operating damage is already in the tape, because investors demand proof that channel inventory is normalizing before paying growth premium again.

The second-order effect is broader skepticism toward any robotics or consumables model with distributor or field-inventory opacity. If channel load-in is still the issue, reported revenue can lag true procedure demand by multiple quarters, which means gross margin and opex leverage can look artificially weak even after end-demand stabilizes. That dynamic hurts PRCT most, but it can also spill into adjacent high-growth medtech names where inventory disclosure is hard to verify.

Near term, the lawsuit itself is mostly an overhang, not a cash event. The real catalysts are the next two earnings prints and any third-party channel checks: if inventory burn does not improve, the market will assume another guidance reset is coming. Conversely, if procedures outrun shipments and management can show the excess inventory is being worked down, the legal discount can unwind quickly over 1-3 months; absent that, the stock can remain range-bound for 6-18 months.

Key Decisions for Investors

• Short PRCT on any post-litigation bounce into the next earnings cycle; use the rally to add rather than chasing weakness. Risk/reward is favorable if channel checks stay soft, but cover if the company shows sequential inventory normalization and no further guidance pressure.
• If options are liquid, buy 1-3 month PRCT put spreads rather than naked puts to define carry; thesis is a near-term multiple compression trade, not a bankruptcy view. Falsifier: guidance raised or sell-through visibly reaccelerates.
• Pair trade: short PRCT vs long ISRG or IHI as a quality/sector hedge. The idea is that this is a company-specific credibility event, not a broad robotic-surgery demand shock.
• Set an alert for the next quarterly print and for any commentary on field inventory or procedure-to-shipment divergence. If the gap persists, expect another leg lower; if it closes, take profits quickly because the legal overhang can de-risk abruptly.